{{cs1 config|name-list-style=vanc|display-authors=6}} {{Drugbox | IUPAC_name = N-(2H-pyrazolo[3,4-b]pyridin-3-yl)-1-(trifluoromethyl)isoquinolin-6-amine | image = Valiglurax.svg | image_class = skin-invert-image | width =
<!--Clinical data--> | tradename = | routes_of_administration =
<!--Identifiers--> | CAS_number = 1976050-09-5 | UNII = | ATC_prefix = | PubChem = 134191471 | IUPHAR_ligand = 10135 | ChemSpiderID = 88296853 | ChEMBL = 4797139
<!--Chemical data--> | C=16 | H=10 | F=3 | N=5 | smiles = C1=CC2=C(NN=C2N=C1)NC3=CC4=C(C=C3)C(=NC=C4)C(F)(F)F | StdInChI = 1S/C16H10F3N5/c17-16(18,19)13-11-4-3-10(8-9(11)5-7-20-13)22-15-12-2-1-6-21-14(12)23-24-15/h1-8H,(H2,21,22,23,24) | StdInChIKey = RUEXKBWCUUFJMY-UHFFFAOYSA-N }}
'''Valiglurax''' ('''VU0652957''') is an experimental drug that is a positive allosteric modulator for the glutamate receptor mGluR4. It was developed as a potential medication for the treatment of Parkinson's disease.<ref>{{cite journal | vauthors = Panarese JD, Engers DW, Wu YJ, Bronson JJ, Macor JE, Chun A, Rodriguez AL, Felts AS, Engers JL, Loch MT, Emmitte KA, Castelhano AL, Kates MJ, Nader MA, Jones CK, Blobaum AL, Conn PJ, Niswender CM, Hopkins CR, Lindsley CW | title = Discovery of VU2957 (Valiglurax): An mGlu<sub>4</sub> Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease | journal = ACS Medicinal Chemistry Letters | volume = 10 | issue = 3 | pages = 255–260 | date = March 2019 | pmid = 30891122 | doi = 10.1021/acsmedchemlett.8b00426 | pmc = 6421540 }}</ref><ref>{{cite journal | vauthors = Panarese JD, Engers DW, Wu YJ, Guernon JM, Chun A, Gregro AR, Bender AM, Capstick RA, Wieting JM, Bronson JJ, Macor JE, Westphal R, Soars M, Engers JE, Felts AS, Rodriguez AL, Emmitte KA, Jones CK, Blobaum AL, Conn PJ, Niswender CM, Hopkins CR, Lindsley CW | title = The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu<sub>4</sub> PAM development candidate | journal = Bioorganic & Medicinal Chemistry Letters | volume = 29 | issue = 2 | pages = 342–346 | date = January 2019 | pmid = 30503632 | doi = 10.1016/j.bmcl.2018.10.050 }}</ref>
== References == {{Reflist}}
Category:Experimental drugs Category:Pyrazolopyridines Category:Isoquinolines Category:Trifluoromethyl compounds Category:Secondary amines
{{nervous-system-drug-stub}}